Stratrix
On the Record · Cigna Group

Cigna Group acquisitions, on the record

The businesses Cigna Group bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand)
Word for word“On July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb INA Holdings, Inc. ("Chubb") for approximately $5.4 billion in cash (the "Chubb transaction") (see Note 4 to the Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K).” 10-K for 2022
divestitureJuly 1, 2022approximately $5.4 billion in cash
Group Disability and Life business
Word for word“The Cigna Group sold its Group Disability and Life business to New York Life Insurance Company for $6.2 billion on December 31, 2020.” 10-K for 2022
divestitureDecember 31, 2020$6.2 billion
Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses
Word for word“In January 2024, we entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S.” 10-K for 2023
agreed divestitureJanuary 2024—
life, accident and supplemental health benefits business in six countries
Word for word“Shareholders' net income decreased 23%, reflecting the estimated loss associated with the sale of our Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses (the "HCSC transaction"), the absence of the gain on the sale of our life, accident and supplemental health benefits business in six countries sold on July 1, 2022 (the "Chubb transaction"), partially offset by foreign deferred tax benefits recorded in the fourth quarter of 2023 as described further under "effective tax rate" below.” 10-K for 2023
divestitureJuly 1, 2022—
Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses
Word for word“In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses (the "Disposal Group") to HCSC subject to applicable regulatory approvals and other customary closing conditions, including purchase price adjustments to align with the final balance sheet of the divested businesses (the "HCSC transaction").” 10-K for 2024
agreed divestitureJanuary 2024—
Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses (sold to Health Care Service Corporation)
Word for word“The final purchase price and total cash proceeds collected in 2025 were $4.9 billion.” 10-K for 2025
divestiture—$4.9 billion
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$4 million—
2017-12-31$209 million$154 million
2018-12-31$24.45 billion$38.37 billion
2019-12-31$153 million$103 million
2020-12-31$139 million$29 million
2021-12-31$1.83 billion$1.44 billion
2022-12-31$0—
2023-12-31$447 million—
2024-12-31$131 million$114 million
2025-12-31$597 million$548 million

Deal filings since 2016

Read from Cigna Group’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.